In practice
Well, imagine Manufacturer A develops and launches a new medicine. They want to sell it to Health System B and they believe a fair price is 100.
In the old World, after lengthy negotiations, loss of value and significant patient frustration, they might agree a heavily discounted price of 50.
In the AIM4ALL World, based on a more readily agreeable standard framework agreement, the Health System might agree an Initial Price of 40 for years one to three and, depending on how the product performs, a price of up to 60 in years four and five and a price of up to 80 in years six and onwards.
Now imagine the AIM4ALL World enhanced further by Remedium working either with the Health System directly or with the Manufacturer.
In this scenario, the Health System would commit to the same pricing; an Initial Price of 40 and, depending on product performance, a price of up to 60 and 80, but the Manufacturer would simply receive a price of 65 guaranteed for 5 years and a price of up to 75 (eventually 80) in years six and onwards; higher upfront cashflows and downside protection, all at an acceptable cost.
In this AIM4ALL (+Remedium) World, everybody wins; Health Systems, Manufacturers and, most importantly, patients.
As one of the World's largest Manufacturers said to us recently, “you really have resolved the bit that we've been struggling with”.